Table 1.
Sample n=434; Black, 57 [13.1], White, 377 [86.9] Patients | Black, n [%] | White, n [%] | P Value |
---|---|---|---|
Age (y), mean (SD) | 54.6 [13.4] | 62.5 [14.8] | 0.000 |
Sex (men) | 30 [52.6] | 224 [59%] | 0.375 |
NYHA Class I | 13 [28.8] | 129 [35.5] | 0.030 |
NYHA Class II | 22 [38.6] | 124 [34.2] | 0.258 |
NYHA Class III and IV | 22 [38.6] | 110 [30.3] | 0.105 |
Max echocardiography LVH, mm, mean (SD) | 19.1 [5.9] | 18.4 [4.9] | 0.838 |
Ejection fraction (echo), mean (SD) | 71.1 [6.1] | 69.6 [6.9] | 0.866 |
LVH distribution (echo data) | |||
Basal LVH | 29 [50.9] | 306 [81.2] | 0.000 |
Sub‐basal LVH | 22 [38.6] | 56 [14.9] | 0.000 |
Diffuse LVH | 6 [10.5] | 15 [4.0] | 0.017 |
Special anatomic features [echo data] | |||
Complete systolic emptying | 9 [15.8] | 30 [7.9] | 0.169 |
Apical aneurysm | 7 [12.3] | 18 [4.75] | 0.055 |
Anomalous papillary muscle | 10 [17.5] | 59 [15.6] | 0.916 |
Obstruction (echo data) | |||
No obstruction | 20 [35.1] | 116 [30.6] | 0.247 |
LVOT obstruction at rest (≥30 mm Hg) | 17 [29.8] | 171 [45.1] | 0.015 |
Provocable LVOT obstruction (Valsalva, standing, exercise) | 13 [22.8] | 71 [18.7] | 0.232 |
Mid‐LV obstruction | 7 [12.3] | 21 [5.5] | 0.025 |
Cardiac MRI data | |||
CMR (had) | 45 [79.0] | 215 [57.6] | 0.009 |
Max CMR LVH, mm, mean (SD) | 22.2 [6.4] | 18.9 [4.7] | 0.017 |
Fibrosis (yes) | 36 [80.0] | 142 [67.3] | 0.121 |
Fibrosis ≥15% (yes) | 10 [22.2] | 19 [8.8] | 0.009 |
CMR indicates cardiac magnetic resonance; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; LVOT, left ventricular outflow tract; mid‐LV, mid‐ventricular; MRI, magnetic resonance imaging; and NYHA, New York Heart Association.